Artivion Future Growth

Future criteria checks 4/6

Artivion is forecast to grow earnings and revenue by 105.6% and 9.8% per annum respectively while EPS is expected to grow by 106.5% per annum.

Key information

105.6%

Earnings growth rate

106.5%

EPS growth rate

Medical Equipment earnings growth	17.4%
Revenue growth rate	9.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	09 Aug 2024

Recent future growth updates

Recent updates

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 13

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Jul 20

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 10

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Mar 09

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Feb 16

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Dec 18

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Sep 29

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Sep 27

Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M

Aug 04

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jun 27

Earnings and Revenue Growth Forecasts

NYSE:AORT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	482	23	N/A	42	3
12/31/2025	431	9	N/A	48	5
12/31/2024	392	3	N/A	43	5
6/30/2024	377	-8	10	19	N/A
3/31/2024	368	-10	6	19	N/A
12/31/2023	354	-31	6	19	N/A
9/30/2023	340	-24	-6	8	N/A
6/30/2023	329	-28	-10	5	N/A
3/31/2023	320	-29	-20	-11	N/A
12/31/2022	314	-19	-14	-5	N/A
9/30/2022	314	-41	-14	-4	N/A
6/30/2022	309	-17	-22	-11	N/A
3/31/2022	305	-15	-15	0	N/A
12/31/2021	299	-15	-16	-3	N/A
9/30/2021	287	2	-11	2	N/A
6/30/2021	280	-12	-3	13	N/A
3/31/2021	258	-13	-5	7	N/A
12/31/2020	253	-17	-1	12	N/A
9/30/2020	255	-14	-5	8	N/A
6/30/2020	258	-11	-10	13	N/A
3/31/2020	275	-5	-7	17	N/A
12/31/2019	276	2	-7	16	N/A
9/30/2019	274	2	4	25	N/A
6/30/2019	271	3	15	21	N/A
3/31/2019	268	1	16	21	N/A
12/31/2018	263	-3	4	10	N/A
9/30/2018	248	-5	-1	5	N/A
6/30/2018	227	-5	-6	0	N/A
3/31/2018	207	-2	N/A	-3	N/A
12/31/2017	190	4	N/A	11	N/A
9/30/2017	182	9	N/A	10	N/A
6/30/2017	183	11	N/A	16	N/A
3/31/2017	182	10	N/A	22	N/A
12/31/2016	180	11	N/A	20	N/A
9/30/2016	175	10	N/A	16	N/A
6/30/2016	167	9	N/A	12	N/A
3/31/2016	155	7	N/A	12	N/A
12/31/2015	146	4	N/A	11	N/A
9/30/2015	143	3	N/A	15	N/A
6/30/2015	144	3	N/A	12	N/A
3/31/2015	143	6	N/A	11	N/A
12/31/2014	145	7	N/A	8	N/A
9/30/2014	142	14	N/A	9	N/A
6/30/2014	141	15	N/A	14	N/A
3/31/2014	140	15	N/A	16	N/A
12/31/2013	141	16	N/A	17	N/A
9/30/2013	138	9	N/A	19	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AORT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: AORT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AORT is expected to become profitable in the next 3 years.

Revenue vs Market: AORT's revenue (9.8% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: AORT's revenue (9.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AORT's Return on Equity is forecast to be high in 3 years time

Artivion Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Artivion, Inc. Revises Earnings Guidance for the Year 2024

Price target increased by 9.2% to US$27.47

Price target increased by 9.2% to US$27.47

Artivion, Inc. Revises Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 880%

Price target increased by 11% to US$25.15

Recent updates

Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Insider notifies of intention to sell stock

Independent Director recently sold US$243k worth of stock

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS exceeds analyst expectations

Artivion, Inc. Revises Earnings Guidance for the Year 2024

Artivion, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Price target increased by 9.2% to US$27.47

Price target increased by 9.2% to US$27.47

Is Artivion (NYSE:AORT) A Risky Investment?

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion, Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Artivion, Inc. to Report Q1, 2024 Results on May 06, 2024

Artivion, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Chairman recently sold US$262k worth of stock

Chairman recently sold US$242k worth of stock

Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 880%

Price target increased by 11% to US$25.15

Artivion, Inc. Provides Earnings Guidance for the Year 2024

Artivion, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Artivion, Inc. announced that it expects to receive $350 million in funding

Is Artivion (NYSE:AORT) Using Too Much Debt?

Senior VP notifies of intention to sell stock

Artivion Stock: A First Assessment

VP & Chief Accounting Officer notifies of intention to sell stock

Artivion, Inc. Announces Chief Financial Officer Changes

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Artivion, Inc. Announces Completion of Enrollment in PERSEVERE Trial

Consensus EPS estimates fall by 29%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. Revises Earnings Guidance for the Year 2023

Artivion, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Artivion, Inc. Announces Data from On-X Aortic Heart Valve Low INR Post-Market Study Presented in A Late-Breaking Science Session At the 37European Association for Cardio-Thoracic Surgery Annual Meeting

Artivion, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Senior Vice President of Operations recently sold US$248k worth of stock

Price target increased by 10% to US$24.90

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Chairman recently sold US$293k worth of stock

Artivion, Inc. Provides Earnings Outlook for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Insider exercised options to buy US$115k worth of stock.

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Artivion, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Price target decreased to US$23.13

Price target decreased to US$23.13

Artivion, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 profit in 3Q 2021)

Artivion, Inc. Provides Revenue Guidance for the Year 2022

Artivion, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Artivion, Inc. Announces the Appointment of Elizabeth A. Hoff to Board of Directors

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Price target decreased to US$26.96

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

Insider recently sold US$125k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind